On March 19, 2019, the Worl∑₹d Intellectual Propert•¥σy Organization (WIPO) publσδ'ished its global intellectual prop™→>erty report 2018.Asian innovators filed more §λπ↓than half of their international patent aφ pplications through WIPO for the f§δ✘irst time in 2018, with significant growtβ$h in China, India and South Korea, the report ∞₩✘noted. As a technology-intensive industry,¥←↓ pharmaceutical industry attaches gr"♦↑eat importance to pateεβ€nt application and intellec§¥tual property protection.
In recent years, '✔the size of the global pharmac↔σγeutical market has maintained a≥ steady growth, with $™China, South Korea, India and other eme↓≈€rging markets presenting a rapid growth momen ↑∑♣tum. With the acceleration of economi₽ c globalization, more and more Chine≠γ$se pharmaceutical companies are entering the ¶€★↕European and American ₽δ₽ markets, and multinational pharmaceut≠φ≈×ical companies are also increαΩβasing their investment in e♣©merging markets.
Due to the different intellectual proper≥"ty policies of different countriβλ€es, the strategic layout of global intellectual p'¶π§roperty, the differences o¥φf pharmaceutical intellectual proα₽<☆perty policies of Asia-♥¶☆pacific countries, the p∏σ§atent review process, litiλ "gation procedures and Generic drug patent≈≤ strategy have gradually become tβ≤"σhe hot spots of the pha≤♦βrmaceutical intellectual property iδndustry.
In this context, the Asia-Pacifi₩φ♦c Pharma Intellectual Property Lea↓Ω♦der Summit will be held in Beijing on Novemb→₹"er 14-15, and will attrac≤↔↓↕t more than 400 industry expΩ€φerts from domestic and foreign pharmaceutical co¶∑mpanies, biotechnology companies, governm≈÷ents, associations, law firms®↓, intellectual property agents and ™Ω≤other companies to attend.